Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
MWN-AI** Summary
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a pioneering company in the field of structural heart medical devices, is set to present at two prominent investor conferences: the TD Cowen 46th Annual Healthcare Conference and the Barclays 28th Annual Healthcare Conference. Wayne Paterson, the Company's Vice Chairman and CEO, will deliver presentations at both events, which are crucial opportunities for Anteris to showcase its innovative solutions for heart disease.
The TD Cowen conference will be held on March 2, 2026, in Boston, MA, featuring a fireside chat with analyst Joshua Jennings from 3:10 PM to 3:40 PM (US EST). The Barclays conference follows shortly after, on March 10, 2026, in Miami Beach, FL, with Paterson engaging in a fireside chat with analyst Matt Miksic from 1:30 PM to 1:55 PM (US EST). Both sessions will include one-on-one meetings and will be available for webcast access via links provided by Anteris, with a replay option available for up to 90 days.
Anteris is renowned for its groundbreaking DurAVR® Transcatheter Heart Valve (THV), designed to treat aortic stenosis, a severe condition caused by the narrowing of the aortic valve. This valve represents a significant advancement in cardiac care, as it combines biomimetic design and ADAPT® tissue technology, which has shown successful use across over 55,000 patients worldwide. The company continues to leverage its strong scientific foundation and experienced team to deliver innovative treatments, addressing critical healthcare needs.
As Anteris prepares for these key presentations, it remains committed to enhancing heart health and expanding its contributions to the field of cardiac solutions.
MWN-AI** Analysis
As Anteris Technologies prepares to present at the TD Cowen and Barclays Healthcare Conferences, investors should closely monitor its developments, particularly surrounding the DurAVR® Transcatheter Heart Valve (THV). This innovative valve is designed to address aortic stenosis, a significant health concern impacting numerous patients globally. Anteris' patented ADAPT® tissue technology, utilized in the DurAVR® THV, has already demonstrated safety and efficacy in over 55,000 patients, establishing a strong foundation for potential sales growth and market capture.
With Vice Chairman and CEO Wayne Paterson speaking at these prominent investor conferences, investor interest could increase due to heightened visibility and stakeholder engagement. The fireside chat format presents a unique opportunity for the CEO to provide insights into Anteris' strategy, ongoing research initiatives, and future commercialization plans. Investors should look for potential guidance on sales projections, expansion plans, or partnerships that could enhance the company's market position.
As the healthcare landscape continues to evolve, particularly with ongoing advancements in cardiac device technology, Anteris is well-positioned to capitalize on this growth. Notably, the biomimetic design of the DurAVR® offers a competitive edge, aligning medical technologies with patient needs more effectively than traditional options.
However, potential investors should remain cautious, given the risks associated with biotechnology and medical device ventures. Market fluctuations, regulatory hurdles, and competitive pressures can impact the company’s stock performance. It would be prudent for investors to assess their risk tolerance and monitor Anteris closely for developments post-conference. Engaging with the archived conference webcasts could provide invaluable context into the company's trajectory and solidify investment decisions moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson will be presenting at both the TD Cowen 46th Annual Healthcare Conference and the Barclays 28th Annual Healthcare Conference.
The details of each conference and how to access them are as follows:
TD Cowen 46th Annual Healthcare Conference
| Date: | Monday, March 2nd, 2026 (US time) |
| Format: | Fireside chat with analyst, Joshua Jennings, and 1x1 meetings |
| Time: | 3:10-3:40PM (US EST) |
| Room: | Provincetown, 4th Floor |
| Location: | Marriott Copley Plaza, Boston, MA |
| Webcast link: | https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/VqMTEJXfhDZmYysHqmpCsL |
Barclays 28th Annual Healthcare Conference
| Date: | Tuesday, March 10th, 2026 (US time) |
| Format: | Fireside chat with analyst, Matt Miksic, and 1x1 meetings |
| Time: | 1:30-1:55PM (US EST) |
| Room: | Americana 2 (Track 2) |
| Location: | Loews Miami Beach Hotel, Miami Beach, FL |
| Webcast link: | https://cc.webcasts.com/barc002/031026a_js/?entity=65_NQYO8PJ |
The webcasts of the TD Cowen and Barclays fireside chats can be accessed by visiting the Investor Center section of the Company’s website at https://anteristech.com/investors/investor-presentations.html. A replay of the webcast will be archived for up to 90 days.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (“THV”), was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
| For more information: | ||
| Global Investor Relations | Investor Relations (US) | |
| investors@anteristech.com | mchatterjee@bplifescience.com | |
| Debbie Ormsby | Malini Chatterjee, Ph.D. | |
| Anteris Technologies Global Corp. | Blueprint Life Science Group | |
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 |
Website www.anteristech.com
X @AnterisTech
LinkedIn https://www.linkedin.com/company/anteristech
FAQ**
How has Anteris Technologies Ltd AMEUF capitalized on its presence in Minneapolis to expand its market reach compared to its operations in Brisbane, Australia?
What strategic advantages does Anteris Technologies Ltd AMEUF gain from being founded in Brisbane while maintaining significant operations in Minneapolis?
How do investor sentiments towards Anteris Technologies Ltd AMEUF differ between the Australian and U.S. markets, particularly in relation to their innovations developed in Minneapolis?
In what ways is Anteris Technologies Ltd AMEUF leveraging its dual presence in Minneapolis and Brisbane to enhance research and development for heart-related medical devices?
**MWN-AI FAQ is based on asking OpenAI questions about Anteris Technologies Global Corp. (NASDAQ: AVR).
NASDAQ: AVR
AVR Trading
6.97% G/L:
$6.75 Last:
558,472 Volume:
$6.65 Open:
